Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Psoriasis ×

Show more Keywords

Table of contents

Select data models

Selected data models

You must log in to select data models for download or further analysis.

34 Search results.

Eligibility NCT00679731 Psoriasis - Eligibility

- 12/9/13 - 1 form, 2 itemgroups, 3 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00679731

Eligibility NCT00233662 Chronic Plaque Psoriasis - Eligibility

- 4/13/14 - 1 form, 3 itemgroups, 32 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria,Medical Concepts

ODM derived from http://clinicaltrials.gov/show/NCT00233662

Eligibility NCT00333411 Psoriasis - Eligibility

- 4/13/14 - 1 form, 3 itemgroups, 53 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria,Medical Concepts

ODM derived from http://clinicaltrials.gov/show/NCT00333411

Eligibility Psoriasis NCT00216879

- 7/9/15 - 1 form, 2 itemgroups, 17 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1

End of Study Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - End of Study Psoriasis MIPSO EudraCT 2014-003022-40

- 8/26/15 - 1 form, 2 itemgroups, 21 items, 2 languages

Itemgroups: End of Study,Studienabbruch Grund RQG

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Personal and Family History of Psoriasis Protocol PhenX Toolkit

- 4/26/16 - 1 form, 1 itemgroup, 28 items, 1 language

Itemgroup: PhenX - personal and family history of psoriasis protocol

The Self Evaluation plus Medication Survey is a self-administered instrument which was developed from the questionnaires used in the Collaborative Association Study of Psoriasis (CASP), which is a Genetic Association Information Network (GAIN) genome-wide association study (GWAS). The Self Evaluation plus Medication Survey collects information on individuals with psoriasis and controls, and their family history of psoriasis and other autoimmune diseases. Additionally, for individuals with psoriasis the questionnaire collects information regarding their symptoms and medication use and its effectiveness. ODM derived from: https://cde.nlm.nih.gov Primary source: https://www.phenxtoolkit.org/ Recent publication: Hendershot, T., Pan, H., Haines, J., Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M., and Hamilton, C.M. (2015) Using the PhenX toolkit to add standard measures to a study. Curr. Protoc. Hum. Genet. 86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86 Permission to publish granted by Carol M. Hamilton.

Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40

- 7/23/16 - 1 form, 2 itemgroups, 7 items, 1 language

Itemgroups: Adalimumab/Ustekinumab,Medication Adalimumab/Ustekinumab

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Medical History Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Medical History Psoriasis MIPSO EudraCT 2014-003022-40

- 7/23/16 - 1 form, 2 itemgroups, 6 items, 1 language

Itemgroups: Prior diseases,Prior diseases

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Adverse Event Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Adverse Event Psoriasis MIPSO EudraCT 2014-003022-40

- 7/23/16 - 1 form, 2 itemgroups, 16 items, 1 language

Itemgroups: Adverse Event,Adverse Event Questionaire

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Demographics Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Demographics Psoriasis MIPSO EudraCT 2014-003022-40

- 7/23/16 - 1 form, 1 itemgroup, 10 items, 1 language

Itemgroup: Demographics

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

- 7/23/16 - 1 form, 6 itemgroups, 54 items, 2 languages

Itemgroups: Patient identification,Inclusion criteria,Exclusion criteria,Additional exclusion criteria Adalimumab,Additional exclusion criteria Ustekinumab,Additional exclusion criteria Cyclosporine

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Ciclosporin Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Ciclosporin Psoriasis MIPSO EudraCT 2014-003022-40

- 7/25/16 - 1 form, 2 itemgroups, 9 items, 1 language

Itemgroups: Cyclosporine,Cyclosporine medication

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.